AILA SOOMRO: Open Payments
NPI 1851949804 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,317 in 29 payments from 12 companies in 2025. Trend: 2023 $412 · 2024 $664 · 2025 $1,317
Food & beverage: $1,317
| Company | Payments | Amount |
|---|---|---|
| AOP Health US, LLC | 1 | $600 |
| PFIZER INC. | 4 | $118 |
| Aimmune Therapeutics, Inc. | 4 | $103 |
| ABBVIE INC. | 3 | $93 |
| Alexion Pharmaceuticals, Inc. | 3 | $80 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $76 |
| CSL Behring | 2 | $65 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $52 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $39 |
| Ferring Pharmaceuticals Inc. | 1 | $36 |
Products named: Rapiblyk, VYNDAQEL, VOWST, DALVANCE, ULTOMIRIS, XIFAXAN, Kcentra, JARDIANCE.
Industry payments across TX — which companies pay providers there.
